All In Biotech

Drug Trial Radar · NCT02993302

Effects Of Oral Alfacalcidol On Maturation Of Dendritic Cells In Graves' Disease Patients

Last checked: Nov 20, 2026Latest source record: Mar 4, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

25

Actual

Start

Jul 2014

Primary completion

Mar 2015

Study completion Mar 2015

Sponsor

Lead sponsor
Dr Cipto Mangunkusumo General HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Universitas Indonesia
First posted
Dec 15, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Maturity level of dendritic cells (DC) plays a pivotal role in initiating and regulating autoimmunity. In Graves' disease (GD), DCs have more active immune responses than those in healthy subjects. Our previous study demonstrated immunoregulatory effects of in vitro 1,25-D3 on maturation of DC in GD patients. This study aims to evaluate the effect of oral 1α-D3 on DC maturation in GD patients.

Conditions

  • Graves Disease

Interventions

  • 1α-D3Drug

    patients were given PTU and 1α-D3

  • PlacebosDrug

    patients were given PTU and placebos

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CD80 LevelTime frame: 1 year
  2. CD206 LevelTime frame: 1 year
  3. IL-12/IL-10 RatioTime frame: 1 year
  4. fT4 LevelsTime frame: 1 year

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.